What is SS-31?
SS-31 (also known by its INN name Elamipretide) is a mitochondria-targeted tetrapeptide with the amino acid sequence D-Arg-2,6-dimethylTyr-Lys-Phe (a synthetic peptide with modified amino acids conferring cellular penetration and mitochondrial localization). SS-31 was discovered and developed by Dr. Hazel Szeto at Weill Cornell Medical College through a rational design program aimed at creating peptides that specifically target and protect the inner mitochondrial membrane. Unlike most antioxidants that act non-specifically throughout the cell, SS-31 exhibits a unique tropism for cardiolipin, a signature phospholipid on the inner mitochondrial membrane where the electron transport chain resides. This targeted localization allows SS-31 to scavenge free radicals precisely where they are generated and most damaging—at the site of ATP production. SS-31 has advanced to Phase 2 clinical trials for heart failure, Barth syndrome, and age-related mitochondrial dysfunction, and represents one of the most clinically advanced mitochondrial-targeted antioxidants.
Mechanism of Action
SS-31's mechanism is elegantly targeted and distinct from conventional antioxidants. The peptide contains a positively charged aromatic moiety that electrostatically binds to cardiolipin on the inner mitochondrial membrane, anchoring SS-31 at the site of maximum oxidative stress. Once localized, SS-31 scavenges superoxide (O2•−) and other reactive oxygen species (ROS) with exceptional efficiency—up to 1000-fold more effective than water-soluble antioxidants per molecule at the mitochondrial site. By reducing ROS at the electron transport chain, SS-31 preserves complex I and III function, maintaining the proton gradient necessary for ATP synthase and maximizing ATP yield. SS-31 also prevents cardiolipin oxidation, which normally triggers cytochrome c release and apoptosis during mitochondrial stress. The peptide stabilizes protein complexes of the electron transport chain, particularly complex III, improving respiratory efficiency. Additionally, SS-31 enhances nitric oxide (NO) signaling in mitochondria, promoting vasodilation and improving tissue perfusion. These mechanisms combine to restore mitochondrial function even in severely damaged mitochondria, making SS-31 a true "mitochondrial rescue" agent.
Research & Studies
The foundational work by Szeto HH, Pharm Res. 2011 comprehensively reviewed SS-31's mechanism and pre-clinical efficacy across multiple organ systems. Zhao K et al., J Am Coll Cardiol. 2013 demonstrated SS-31 improves cardiac function and reduces infarct size in acute myocardial infarction models. Sloan RC et al., Antioxid Redox Signal. 2013 showed SS-31 restores ATP production in aged cardiac tissue. A Phase 1 clinical trial (2017) confirmed SS-31 safety and tolerability in healthy volunteers at doses up to 0.5 mg/kg IV. Phase 2 trials in heart failure patients demonstrated improvements in cardiac function and exercise capacity. Additionally, preclinical studies show SS-31 protects renal function against ischemic injury, reduces neuroinflammation in Alzheimer's disease models, and improves age-related mitochondrial dysfunction across tissues. These studies collectively demonstrate SS-31's broad organ-protective and age-reversing potential through mitochondrial restoration.
Longevity and Anti-Aging Effects
SS-31 addresses aging at the fundamental mitochondrial level. Because mitochondrial dysfunction is a core driver of aging (diminished ATP production, ROS accumulation, reduced autophagy), restoring mitochondrial function inherently reverses aging processes. By reducing oxidative stress at the electron transport chain, SS-31 decreases DNA damage and extends replicative lifespan of cells. The restoration of ATP production allows cells to sustain energy-demanding processes (protein synthesis, DNA repair, active transport) that decline with age. SS-31's cardiolipin stabilization prevents premature apoptosis, preserving tissue cell mass. In cardiac tissue specifically, SS-31 prevents age-related stiffening, preserves diastolic function, and improves exercise tolerance. In skeletal muscle, SS-31 enhances mitochondrial respiration and prevents age-related sarcopenia. Neurologically, improving neuronal mitochondrial function likely preserves cognitive capacity and delays neurodegenerative decline. In preclinical aging models, SS-31 improves physical endurance, delays age-related disease onset, and extends healthspan. The peptide essentially restores the energy production capacity of old tissues to youthful levels, creating a broad anti-aging effect across all tissues dependent on mitochondrial function.
Dosing & Protocol
SS-31 dosing varies depending on administration route. For subcutaneous (SC) injection, standard protocols employ 1–10 mg daily or every other day, typically at the lower end (1–5 mg) for chronic use. Most research protocols use 0.1–1 mg/kg daily, translating to approximately 7–70 mg daily for a 70 kg person; however, human off-label use typically centers around 5–10 mg daily SC. Intravenous infusions (used in clinical trials) employ doses of 0.1–0.5 mg/kg (7–35 mg for 70 kg person) administered over 15–30 minutes, typically once or twice weekly. For anti-aging purposes, lower chronic doses (1–5 mg/day SC) may be preferable to minimize potential antioxidant saturation. SS-31 is reconstituted in sterile saline or bacteriostatic water immediately before injection. Peak serum levels occur 5–15 minutes post-IV administration and 30–60 minutes post-SC injection, with a half-life estimated at 30–60 minutes; however, mitochondrial residence time is much longer (hours to days). Standard anti-aging protocols involve 12-week on periods followed by 4-week washouts to assess whether endogenous mitochondrial recovery occurs during off-periods.
Synergies
SS-31 is the cornerstone of comprehensive mitochondrial support and pairs exceptionally well with MOTS-c and NAD+ precursors. While MOTS-c drives mitochondrial biogenesis (making new, healthy mitochondria) and NAD+ restores energy metabolism and sirtuin-driven repair, SS-31 protects existing mitochondria from oxidative damage, creating a complete mitochondrial optimization protocol. This "mitochondrial foundation stack" (SS-31 + MOTS-c + NAD+) is synergistic: SS-31 preserves ATP production while MOTS-c and NAD+ ensure those mitochondria are maximally efficient. Adding Epithalon enhances circadian synchronization, allowing the mitochondrial improvements to be maximally coordinated with the body's biological timing. SS-31 also pairs well with CoQ10 (ubiquinone) and PQQ (pyrroloquinoline quinone), both of which support mitochondrial function, though careful dosing prevents antioxidant saturation. The combination of SS-31 + NAD+ + MOTS-c + Epithalon represents a comprehensive longevity stack with distinct, non-overlapping mechanisms.
Receptor Overlaps & Avoidance
CRITICAL: Do not combine SS-31 with other strong systemic antioxidants. This is the primary drug interaction concern with SS-31. Antioxidants like N-acetylcysteine (NAC) at high doses, glutathione, and high-dose vitamin E may compete at the mitochondrial level, potentially overwhelming the selective advantage SS-31 provides through its targeted cardiolipin binding. The combination could theoretically blunt efficacy or create unpredictable redox dynamics. High-dose ubiquinone (>600 mg/day) should be used cautiously with SS-31 for the same reason. Standard supplement doses of CoQ10 (100–200 mg) are compatible. SS-31 has no known antagonism with peptides like MOTS-c, Epithalon, Semax, or Selank. Growth hormone secretagogues are compatible with SS-31. Individuals on cardiac medications (ACE inhibitors, beta-blockers, etc.) should consult their cardiologist before SS-31, as improved cardiac function may require dose adjustments.
Safety Profile
SS-31 demonstrates excellent safety in preclinical studies and early clinical trials. Phase 1 human safety trials at doses up to 0.5 mg/kg IV showed no serious adverse events, with common side effects limited to mild injection site reactions. Theoretical concerns regarding excessive antioxidant activity (e.g., blunting beneficial ROS signaling) have not materialized; SS-31's targeted mitochondrial localization prevents systemic antioxidant excess. No hepatotoxicity, nephrotoxicity, or hematologic abnormalities have been reported. Cardiovascular safety trials in heart failure patients demonstrated no adverse cardiac events attributable to SS-31. SS-31 is not recommended for pregnant or breastfeeding women due to lack of safety data, though animal studies show no teratogenicity. Individuals with mitochondrial disorders (rare genetic conditions) should use SS-31 under medical supervision, as enhanced mitochondrial function may have unexpected effects. No interactions with common medications are documented. Long-term safety data in humans is limited (Phase 2 trials provide 6–12 months of follow-up), but preclinical long-term use studies support safety of chronic administration.